CN113214278B - 新型Jak1选择性抑制剂及其用途 - Google Patents

新型Jak1选择性抑制剂及其用途 Download PDF

Info

Publication number
CN113214278B
CN113214278B CN202110514751.5A CN202110514751A CN113214278B CN 113214278 B CN113214278 B CN 113214278B CN 202110514751 A CN202110514751 A CN 202110514751A CN 113214278 B CN113214278 B CN 113214278B
Authority
CN
China
Prior art keywords
compound
formula
pyridin
imidazo
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110514751.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN113214278A (zh
Inventor
梁从新
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Gaoguang Pharmaceutical Co ltd
Original Assignee
Hangzhou Gaoguang Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Gaoguang Pharmaceutical Co ltd filed Critical Hangzhou Gaoguang Pharmaceutical Co ltd
Publication of CN113214278A publication Critical patent/CN113214278A/zh
Application granted granted Critical
Publication of CN113214278B publication Critical patent/CN113214278B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN202110514751.5A 2016-10-03 2017-09-30 新型Jak1选择性抑制剂及其用途 Active CN113214278B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662403660P 2016-10-03 2016-10-03
US62/403,660 2016-10-03
PCT/US2017/054668 WO2018067422A1 (en) 2016-10-03 2017-09-30 Novel jak1 selective inhibitors and uses thereof
CN201780004442.5A CN108366994B (zh) 2016-10-03 2017-09-30 新型Jak1选择性抑制剂及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780004442.5A Division CN108366994B (zh) 2016-10-03 2017-09-30 新型Jak1选择性抑制剂及其用途

Publications (2)

Publication Number Publication Date
CN113214278A CN113214278A (zh) 2021-08-06
CN113214278B true CN113214278B (zh) 2022-10-28

Family

ID=61831161

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110514751.5A Active CN113214278B (zh) 2016-10-03 2017-09-30 新型Jak1选择性抑制剂及其用途
CN201780004442.5A Active CN108366994B (zh) 2016-10-03 2017-09-30 新型Jak1选择性抑制剂及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780004442.5A Active CN108366994B (zh) 2016-10-03 2017-09-30 新型Jak1选择性抑制剂及其用途

Country Status (19)

Country Link
US (3) USRE50799E1 (https=)
EP (1) EP3509591B1 (https=)
JP (1) JP7089141B2 (https=)
KR (1) KR102399848B1 (https=)
CN (2) CN113214278B (https=)
AU (3) AU2017339417C1 (https=)
DK (1) DK3509591T3 (https=)
EA (1) EA201990523A1 (https=)
ES (1) ES2901216T3 (https=)
HK (1) HK1253040A1 (https=)
HR (1) HRP20211965T1 (https=)
HU (1) HUE058120T2 (https=)
IL (3) IL265358B (https=)
MX (1) MX390005B (https=)
NZ (1) NZ751284A (https=)
PL (1) PL3509591T3 (https=)
PT (1) PT3509591T (https=)
RS (1) RS62695B1 (https=)
WO (1) WO2018067422A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102399848B1 (ko) 2016-10-03 2022-05-19 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 신규한 jak1 선택적 억제제 및 그 용도
PL3568396T3 (pl) 2017-01-11 2021-05-31 Leo Pharma A/S Nowe pochodne aminoimidazopirydyny jako inhibitory kinaz janusowych i ich zastosowanie farmaceutyczne
CA3117969A1 (en) 2018-10-31 2020-05-07 Incyte Corporation Combination therapy for treatment of hematological diseases
MA55201A (fr) * 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
IL318796A (en) * 2019-06-06 2025-04-01 Hangzhou Highlightll Pharmaceutical Co Ltd Method for preparing a furoimidazopyridine compound, polymorph and salt polymorph
KR102785014B1 (ko) * 2019-06-06 2025-03-20 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태
CN115803317B (zh) 2020-05-19 2025-07-15 拜耳作物科学股份公司 作为杀真菌化合物的氮杂双环(硫代)酰胺
WO2021249995A1 (en) 2020-06-10 2021-12-16 Bayer Aktiengesellschaft Azabicyclyl-substituted heterocycles as fungicides
EP4351584A4 (en) * 2021-06-07 2025-04-23 The Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING CELIAC DISEASE
EP4419101A4 (en) * 2021-09-13 2025-09-03 Hangzhou Highlightll Pharmaceutical Co Ltd METHODS OF TREATMENT OF CNS DISORDERS
CN114213424B (zh) 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法
WO2025224600A1 (en) * 2024-04-21 2025-10-30 Biohaven Therapeutics Ltd. Treatment of alpha-synucleinopathies and neuroprotection
WO2025248468A1 (en) 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria)
WO2026002028A1 (zh) * 2024-06-26 2026-01-02 杭州多域生物技术有限公司 稠杂芳环类化合物、其药物组合物及其应用
WO2026032213A1 (zh) * 2024-08-08 2026-02-12 普罗思特(南京)生物科技有限公司 取代的三环衍生物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101277963A (zh) * 2005-08-04 2008-10-01 西特里斯药业公司 作为sirtuin调节剂的噁唑并吡啶衍生物
WO2012022045A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
CN102741253A (zh) * 2009-09-29 2012-10-17 艾科睿控股公司 PI3K(δ)选择性抑制剂
CN103442568A (zh) * 2010-10-08 2013-12-11 Abbvie公司 呋喃并[3,2-d]嘧啶化合物
CN104918945A (zh) * 2012-11-01 2015-09-16 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983092A (en) 1975-01-20 1976-09-28 Ciba-Geigy Corporation Phenylindane diamine mixture and epoxy resin therewith
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
DE69924735T2 (de) 1998-07-28 2006-01-19 Tanabe Seiyaku Co., Ltd. Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6800663B2 (en) 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
US20070185152A1 (en) 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
CN101238186B (zh) 2005-08-11 2012-10-24 3M创新有限公司 作为金属基底涂层的互穿聚合物网络及其制造方法
WO2007039146A1 (en) 2005-09-23 2007-04-12 Smithkline Beecham Corporation 4-carboxy pyrazole derivatives as anti-viral agents
US7879968B2 (en) 2006-10-17 2011-02-01 Taylor Made Golf Company, Inc. Polymer compositions and golf balls with reduced yellowing
US20100280151A1 (en) 2009-05-04 2010-11-04 Toray Industries, Inc. Toughened fiber reinforced polymer composite with core-shell particles
WO2011138657A1 (en) 2010-05-04 2011-11-10 Glenmark Pharmaceuticals S.A. Aryl substituted olefinic compounds as pde10a inhibitors
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
AU2012295802B2 (en) 2011-08-12 2017-03-30 Nissan Chemical Industries, Ltd. Tricyclic heterocyclic compounds and JAK inhibitors
JP6057907B2 (ja) 2011-10-04 2017-01-11 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とする医薬品
CN103450125B (zh) 2013-07-18 2016-01-13 嘉兴中科化学有限公司 一种5-取代苯丙呋喃-2-羧酸及其衍生物的合成方法
EP3060234A1 (en) 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
CN106687462A (zh) 2014-04-30 2017-05-17 因赛特公司 Jak1抑制剂的制备方法以及其新形式
EP2940022B1 (en) 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CN105418620B (zh) 2014-09-23 2018-05-04 天津药明康德新药开发有限公司 一种4-(叔丁氧羰基)八氢呋喃并[3,2-b]吡啶-6-羧酸的合成方法
WO2016100349A2 (en) 2014-12-16 2016-06-23 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
CN106432232A (zh) 2016-09-18 2017-02-22 苏州汉德创宏生化科技有限公司 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法
KR102399848B1 (ko) 2016-10-03 2022-05-19 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 신규한 jak1 선택적 억제제 및 그 용도
LT3555097T (lt) 2016-12-16 2022-08-25 Janssen Pharmaceutica Nv Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
CN107216334A (zh) 2017-06-29 2017-09-29 上海吉尔多肽有限公司 一种6‑氯呋喃[3,2‑b]吡啶的合成方法
KR102785014B1 (ko) 2019-06-06 2025-03-20 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태
IL318796A (en) 2019-06-06 2025-04-01 Hangzhou Highlightll Pharmaceutical Co Ltd Method for preparing a furoimidazopyridine compound, polymorph and salt polymorph
CN118619944A (zh) 2019-06-06 2024-09-10 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
CN114213424B (zh) 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101277963A (zh) * 2005-08-04 2008-10-01 西特里斯药业公司 作为sirtuin调节剂的噁唑并吡啶衍生物
CN102741253A (zh) * 2009-09-29 2012-10-17 艾科睿控股公司 PI3K(δ)选择性抑制剂
WO2012022045A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
CN103442568A (zh) * 2010-10-08 2013-12-11 Abbvie公司 呋喃并[3,2-d]嘧啶化合物
CN104918945A (zh) * 2012-11-01 2015-09-16 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物

Also Published As

Publication number Publication date
AU2022201061B2 (en) 2023-03-16
IL291267B1 (en) 2023-01-01
KR102399848B1 (ko) 2022-05-19
MX390005B (es) 2025-03-20
IL265358A (en) 2019-05-30
HUE058120T2 (hu) 2022-07-28
USRE49834E1 (en) 2024-02-13
WO2018067422A1 (en) 2018-04-12
MX2019003649A (es) 2019-08-14
KR20190057069A (ko) 2019-05-27
CN108366994A (zh) 2018-08-03
AU2017339417A1 (en) 2019-03-28
BR112019005969A2 (pt) 2019-06-18
EP3509591A1 (en) 2019-07-17
IL291267A (en) 2022-05-01
IL291265A (en) 2022-05-01
EP3509591B1 (en) 2021-11-17
PL3509591T3 (pl) 2022-01-31
AU2022201058B2 (en) 2023-03-16
HK1253040A1 (zh) 2019-06-06
IL291265B1 (en) 2023-01-01
AU2017339417C1 (en) 2022-06-02
AU2022201061A1 (en) 2022-03-10
ES2901216T3 (es) 2022-03-21
USRE50799E1 (en) 2026-02-17
US20190256523A1 (en) 2019-08-22
IL291265B2 (en) 2023-05-01
RS62695B1 (sr) 2022-01-31
CA3039178A1 (en) 2018-04-12
PT3509591T (pt) 2021-12-27
CN113214278A (zh) 2021-08-06
DK3509591T3 (da) 2021-12-20
EP3509591A4 (en) 2020-03-25
IL291267B2 (en) 2023-05-01
NZ751284A (en) 2022-09-30
EA201990523A1 (ru) 2019-10-31
AU2017339417B2 (en) 2021-11-18
AU2022201058A1 (en) 2022-03-10
US10738060B2 (en) 2020-08-11
CN108366994B (zh) 2021-10-01
IL265358B (en) 2022-04-01
HRP20211965T1 (hr) 2022-03-18
JP2019537559A (ja) 2019-12-26
JP7089141B2 (ja) 2022-06-22

Similar Documents

Publication Publication Date Title
CN113214278B (zh) 新型Jak1选择性抑制剂及其用途
US11827638B2 (en) Imidazopyrrolopyridine as inhibitors of the JAK family of kinases
CN112368278B (zh) Rip1抑制性化合物以及制备和使用其的方法
AU2017377069A1 (en) Small molecule inhibitors of the JAK family of kinases
CN111801100B (zh) 用于治疗和预防肝癌的7-取代的磺亚氨酰基嘌呤酮化合物和衍生物
EP3328496A1 (en) Inhibitors of ack1/tnk2 tyrosine kinase
TW202214603A (zh) 一種噠嗪類衍生物游離鹼晶型及其製備方法和應用
WO2019070167A1 (ru) Ингибиторы рецептора эпидермального фактора роста
HK40047523A (en) Novel jak1 selective inhibitors and uses thereof
HK40047523B (en) Novel jak1 selective inhibitors and uses thereof
CA3039178C (en) Novel jak1 selective inhibitors and uses thereof
HK40004735B (en) Novel jak1 selective inhibitors and uses thereof
EA040948B1 (ru) Селективные ингибиторы jak1 и их применение
BR112019005969B1 (pt) Inibidores seletivos de jak1 e usos dos mesmos
HK40079587B (zh) 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用
EA052543B1 (ru) Пролекарства ингибиторов stat3

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40047523

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant